Lanthane Viatris (Lanthanum)

Lanthanum acts locally in the gastrointestinal tract, where it binds dietary phosphate ions to form insoluble lanthanum‑phosphate complexes. These complexes are not absorbed and are eliminated in the feces, thereby decreasing the amount of phosphate that enters the bloodstream and lowering serum phosphate concentrations.

The appropriate dose of Lanthane Viatris is determined by the prescribing clinician based on the patient’s serum phosphate levels, dietary intake, and dialysis regimen. The prescriber will adjust the amount to achieve the desired phosphate control while monitoring for safety.

Safety data for lanthanum‑based phosphate binders in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Compared with calcium‑based binders, lanthanum does not increase calcium load, reducing the risk of hypercalcemia. Unlike sevelamer, lanthanum generally has a lower pill burden and does not affect lipid profiles. Choice of binder depends on individual patient factors, tolerability, and physician preference.

Store Lanthane Viatris at temperatures below 25 °C in its original packaging. Protect the product from moisture, direct sunlight, and extreme humidity. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Lanthane Viatris is taken orally, usually with meals. The tablets should be swallowed whole with a full glass of water unless the prescribing information advises otherwise. Consistency in timing with respect to food helps maintain optimal phosphate‑binding efficacy.

The most serious adverse events include severe constipation that can progress to bowel obstruction, marked hypophosphatemia leading to muscle weakness or cardiac issues, and gastrointestinal ulceration or bleeding. Patients should report any persistent abdominal pain, inability to pass stool, or signs of bleeding promptly.

Lanthane Viatris should be avoided in patients with known hypersensitivity to lanthanum or any excipients, those with active gastrointestinal obstruction, severe bowel disorders, or conditions that predispose to ulceration. It is also contraindicated in individuals for whom phosphate binding is not clinically indicated.